Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Protein or biologic · Fusion protein
Detailed molecular class: Soluble activin receptor fusion protein
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
ActRIIB ligand trap, affecting myostatin-related signaling.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance
ActRIIB ligand-trap fusion protein, not a simple myostatin-inhibitor injection interchangeable with other products.
Human evidence
Randomized Duchenne muscular dystrophy trial was stopped early for safety concerns; exploratory trends are not established functional benefit.
Preclinical evidence
Muscle-growth rationale does not establish improved clinical function.
Critical reading and limitations
A Duchenne trial stopped for safety; exploratory trends do not prove improved clinical function.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Epistaxis and telangiectasias were reported; safety cannot be inferred from lean-mass changes.
Epistaxis/telangiectasias and off-target effects show why increased mass does not establish safety.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID27462804 · Randomized controlled trial
Boys with Duchenne muscular dystrophy.
SC every 2–4 weeks, ascending trial.
Stopped for epistaxis/telangiectasias; functional trends were nonsignificant.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
ACE-031 · 4 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT01099761 · Study of ACE-031 in Subjects With Duchenne Muscular DystrophyRegistry status: TerminatedLast update posted: October 13, 2022Query verification: October 16, 2026
NCT01239758 · Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyRegistry status: TerminatedLast update posted: February 1, 2013Query verification: October 16, 2026
NCT00952887 · A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal WomenRegistry status: CompletedLast update posted: March 23, 2011Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID27462804
Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM.
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026